Biopharmaceutical giant Oxigene Inc (NASDAQ:OXGN) y reported its experimental drug Zybrestat, combined with Roche’s cancer drug Avastin, significantly slowed progression of recurrent ovarian cancer. OXiGENE Inc (NASDAQ:OXGN) stock performance was 77.27% in last session and finished the day at $4.29. Traded volume was 29,290,814 million shares in the last session and the average volume of the stock remained 569.72 million shares. The beta of the stock remained 2.72. OXiGENE Inc (NASDAQ:OXGN) insider ownership is 0.10%.

Cell Therapeutics Inc (NASDAQ:CTIC) reported financial results for the fourth quarter and full year ended Dec. 31, 2013. For the quarter and the full year ended Dec. 31, 2013, CTIC reported revenue of $32.9 million and $34.7 million, respectively, compared with no revenue for the same periods in 2012. For the fourth quarter, CTIC reported a net income of $10.2 million, or $0.08 per share, compared to a net loss of $19.0 million, or ($0.20) per share, for the same period in 2012. Cell Therapeutics Inc (NASDAQ:CTIC) rose 8.18 percent to $4.10 yesterday on volume of 10.47 million shares. The intra-day range of the stock was $3.80 to $4.11. Cell Therapeutics Inc (NASDAQ:CTIC) has a market capitalization of $ 613.51 million.

The Compensation Committee of the Board of Directors of ARCA biopharma, Inc. (NASDAQ:ABIO) (approved cash bonuses (the “Bonuses”) for each of the executive officers of the Company. Arca Biopharma Inc (NASDAQ:ABIO)’s stock on Mar 12, 2014 reported a increase of 11.34% to the closing price of $2.16. Its fifty two weeks range is $1.13 -$3.93. The total market capitalization recorded $34.22 million. The overall volume in the last trading session was 4,733,955 million shares. In its share capital, Arca Biopharma Inc (NASDAQ:ABIO) has 10.83 million outstanding shares.

Shares of NPS Pharmaceuticals (NASDAQ:NPSP) have received an average recommendation of “Buy” from the fifteen analysts that are covering the stock, AnalystRatingsNetwork reports. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. On Wednesday, shares of NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) advanced 5.86% to close the day at $33.97. Company return on investment (ROI) is -0.70% and its monthly performance is recorded as -4.98%. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) quarterly revenue growth is 42.19%.